Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dinutuximab beta - Children's Cancer Research Institute/EUSA Pharma

Next Previous
Drug Profile

Dinutuximab beta - Children's Cancer Research Institute/EUSA Pharma

Alternative Names: APN 311; ch14.18/CHO; ISQETTE; QARZIBA; Qarziba

Latest Information Update: 14 Jun 2025

Price :
€55 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Children's Cancer Research Institute
  • Developer Apeiron Biologics; BeOne Medicines; Children's Cancer Research Institute; EUSA Pharma; Nagoya University; SIOPEN
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroblastoma

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 28 Jun 2023 BeiGene completes a phase I trial in (In infants, In adolescents, In adults, In the elderly) in China (IV) (NCT05373901)
  • 02 Jun 2023 Updated efficacy data from the phase III SIOPEN trial in Neuroblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top